Abstract
Background: Ovarian cancer is the most malignant tumor in gynecological tumors, with low five-year survival rate. The main reasons are diagnosis at advanced stages (the early symptoms are uncharacteristic, and most are diagnosedlate.), relapse, and resistance to existing chemotherapy drugs.
Methods: Search strategy was performed in the following steps. Firstly, LncRNA related to ovarian cancer was retrieved by using the LncRNA Disease database, and articles were searched by searching keywords: ovarian cancer, drug resistance, and LncRNA retrieved from the LncRNA Disease database.
Results/Conclusion: With the development of the study on drug resistance of ovarian cancer, the role of LncRNAs as sensitive biomarker and therapeutic target has emerged, providing a direction for precision medicine of ovarian cancer resistance.
Keywords: Ovarian cancer, chemoresistance, long non-coding RNA, LncRNA, drug resistance, gynecological tumors.
Current Pharmaceutical Design
Title:The Regulatory Roles of Long Non-Coding RNA in the Chemoresistance Process of Ovarian cancer
Volume: 25 Issue: 8
Author(s): Jiayuan Qu, Mohammad Amjad Kamal and Chengfu Yuan*
Affiliation:
- Department of Biochemistry, China Three Gorges University, Yichang 443002,China
Keywords: Ovarian cancer, chemoresistance, long non-coding RNA, LncRNA, drug resistance, gynecological tumors.
Abstract:
Background: Ovarian cancer is the most malignant tumor in gynecological tumors, with low five-year survival rate. The main reasons are diagnosis at advanced stages (the early symptoms are uncharacteristic, and most are diagnosedlate.), relapse, and resistance to existing chemotherapy drugs.
Methods: Search strategy was performed in the following steps. Firstly, LncRNA related to ovarian cancer was retrieved by using the LncRNA Disease database, and articles were searched by searching keywords: ovarian cancer, drug resistance, and LncRNA retrieved from the LncRNA Disease database.
Results/Conclusion: With the development of the study on drug resistance of ovarian cancer, the role of LncRNAs as sensitive biomarker and therapeutic target has emerged, providing a direction for precision medicine of ovarian cancer resistance.
Export Options
About this article
Cite this article as:
Qu Jiayuan, Kamal Amjad Mohammad and Yuan Chengfu*, The Regulatory Roles of Long Non-Coding RNA in the Chemoresistance Process of Ovarian cancer , Current Pharmaceutical Design 2019; 25 (8) . https://dx.doi.org/10.2174/1381612825666190404122154
DOI https://dx.doi.org/10.2174/1381612825666190404122154 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Solubilization and Antitumor Activity of Oleanolic Acid Lysinate
Current Analytical Chemistry Ceramide in Chemotherapy of Tumors
Recent Patents on Anti-Cancer Drug Discovery Targeting DNA Repair Proteins: A Promising Avenue for Cancer Gene Therapy
Current Gene Therapy Up-regulation of microRNA-16 in Glioblastoma Inhibits the Function of Endothelial Cells and Tumor Angiogenesis by Targeting Bmi-1
Anti-Cancer Agents in Medicinal Chemistry Potential of Plant-Derived Natural Products in the Treatment of Leukemia and Lymphoma
Current Drug Targets Irreversible LSD1 Inhibitors: Application of Tranylcypromine and Its Derivatives in Cancer Treatment
Current Topics in Medicinal Chemistry Recent Advances in Curcumin Nanocarriers for the Treatment of Different Types of Cancer with Special Emphasis on In Vitro Cytotoxicity and Cellular Uptake Studies
Nanoscience & Nanotechnology-Asia MicroRNA-34a and its target genes: Key factors in cancer multidrug resistance
Current Pharmaceutical Design Current Status of Magnetite-Based Core@Shell Structures for Diagnosis and Therapy in Oncology Short running title: Biomedical Applications of Magnetite@Shell Structures
Current Pharmaceutical Design mTOR Targeted Cancer Chemoprevention by Flavonoids
Current Medicinal Chemistry Functions of MAPR (Membrane-Associated Progesterone Receptor) Family Members As Heme/Steroid-Binding Proteins
Current Protein & Peptide Science Potential Role of <i>In Vitro-In Vivo</i> Correlations (IVIVC) for the Development of Plant-Derived Anticancer Drugs
Current Drug Targets Structural Aspects of Crystalline Derivatized Cyclodextrins and Their Inclusion Complexes
Current Organic Chemistry Paclitaxel Nanoparticles Induce Apoptosis and Regulate TXR1, CYP3A4 and CYP2C8 in Breast Cancer and Hepatoma Cells
Anti-Cancer Agents in Medicinal Chemistry Potential Applications of Bacterial Cellulose in Environmental and Pharmaceutical Sectors
Current Pharmaceutical Design Interaction of Autophagy and Toll-Like Receptors: A Regulatory Cross- Talk - Even in Cancer Cells?
Current Drug Targets Roles of NHERF1/EBP50 in Cancer
Current Molecular Medicine Scheduling of Taxanes: A Review
Current Clinical Pharmacology Possibilities of Poly(D,L-lactide-co-glycolide) in the Formulation of Nanomedicines Against Cancer
Current Drug Targets Key Roles of MicroRNA-22 Family in Complex Organisms Inferred from its Evolution
MicroRNA